2m 2m 2m 2m 2m 2m 2m
KARYOPHARM THER (KPTI)
NASDAQ
$9.02+$0.02 (+0.17%)
Price as of Jun 03, 2026 6:03 PM EDT- $206.2MMarket Cap
- 117.18%1-Year Change
- BiotechnologyIndustry
KARYOPHARM THER (KPTI)
$9.02+$0.02 (+0.17%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 114.9M -20.92% | 145.2M -0.55% | 146.0M -7.03% | 157.1M -25.14% | |
Cost of Revenue | 5.9M +2,520.70% | 227,000 -95.41% | 4.9M -5.20% | 5.2M +53.23% | |
Gross Profit | 108.9M -24.90% | 145.0M +2.78% | 141.1M -7.09% | 151.9M -26.43% | |
Sales and Marketing Expense | 105.2M -8.86% | 115.4M -12.47% | 131.9M -9.30% | 145.4M +1.08% | |
Research and Development Expense | -125.6M -12.30% | -143.2M +3.23% | -138.8M -6.67% | -148.7M -7.57% | |
Depreciation and Amortization Expense | 296,000 -12.94% | 340,000 -35.85% | 530,000 -14.65% | 621,000 -21.29% | |
Total Operating Expenses | 236.8M -10.54% | 264.7M -3.95% | 275.6M -7.92% | 299.3M -2.86% | |
Operating Profit | -90.7M -24.06% | -119.4M -7.79% | -129.5M -8.90% | -142.2M +44.70% | |
Interest Income | 2.8M -62.53% | 7.4M -32.38% | 10.9M +363.88% | 2.4M +305.33% | |
Interest Expense | -2.7M 0.00% | -2.7M -88.52% | -23.8M -4.69% | -25.0M -4.03% | |
Interest Income and Expense and Net | 37,000 -99.21% | 4.7M +136.21% | -12.9M -43.10% | -22.6M -11.10% | |
Total Nonoperating Income and Expense | -105.3M -344.41% | 43.1M +425.46% | -13.2M -41.74% | -22.7M -11.07% | |
Income before Taxes | -196.0M +156.66% | -76.4M -46.51% | -142.8M -13.43% | -164.9M +33.19% | |
Income Taxes | 43,000 -24.56% | 57,000 -82.35% | 323,000 -12.47% | 369,000 +37.69% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -196.0M +156.52% | -76.4M -46.60% | -143.1M -13.43% | -165.3M +33.20% | |
Net Income from Continuing Operations Applicable to Common | -196.0M +156.66% | -76.4M -46.51% | -142.8M -13.43% | -164.9M +33.19% | |
Basic EPS and Net Income | -17.93 +2,746.03% | -0.63 -49.60% | -1.25 -38.12% | -2.02 +22.42% | |
Diluted EPS and Net Income | -17.93 +1,827.96% | -0.93 -25.60% | -1.25 -38.12% | -2.02 +22.42% | |
Basic Weighted Average Shares | 10,935 -91.03% | 121,863 -99.89% | 114.2M +39.51% | 81.9M +8.84% | |
Diluted Weighted Average Shares | 10,935 -91.38% | 126,809 -99.89% | 114.2M +39.51% | 81.9M +8.84% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 60.5M -3.10% | 62.5M +19.61% | 52.2M -61.36% | 135.2M -29.02% | |
Short-Term Investments | 3.2M -93.07% | 46.2M -66.79% | 139.2M -2.50% | 142.8M +274.20% | |
Cash and Cash Equivalents and Short-Term Investments | 63.7M -41.36% | 108.7M -43.21% | 191.4M -31.13% | 278.0M +21.59% | |
Total Current Assets | 103.1M -34.09% | 156.5M -33.10% | 233.9M -33.20% | 350.2M +27.05% | |
Accumulated Depreciation | 5.5M -17.65% | 6.7M +1.92% | 6.6M -1.20% | 6.6M +9.71% | |
Property and Plant and Equipment and Net | 104,000 -74.00% | 400,000 -33.99% | 606,000 -46.80% | 1.1M -30.63% | |
Total Long-Term Assets | 267,000 -79.99% | 1.3M 0.00% | 1.3M N/A | 0 -100.00% | |
Total Assets | 108.4M -34.06% | 164.4M -31.62% | 240.4M -32.87% | 358.2M +17.32% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 21.0M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 92.1M -0.22% | 92.3M +32.79% | 69.5M +5.42% | 65.9M -10.59% | |
Total Long-Term Debt | 94.8M +0.20% | 94.6M -44.65% | 170.9M +0.48% | 170.1M +0.48% | |
Total Long-Term Liabilities | 11.1M +356.58% | 2.4M +148.47% | 978,000 -83.96% | 6.1M -32.02% | |
Total Liabilities | 401.3M +14.53% | 350.4M -6.96% | 376.6M +0.48% | 374.8M -2.64% | |
Retained Earnings | -1.8B +12.54% | -1.6B +5.14% | -1.5B +10.65% | -1.3B +14.02% | |
Total Stockholders Equity | -292.9M +57.47% | -186.0M +36.57% | -136.2M +717.76% | -16.7M -79.09% | |
Total Shares Outstanding | 18.3M -85.49% | 126.2M +9.82% | 114.9M +1.50% | 113.2M +49.46% | |
Cash Flow | |||||
Cash from Operating Activities | -75.4M -40.88% | -127.5M +37.49% | -92.7M -38.00% | -149.6M +39.62% | |
Capital Expenditures | 0 -100.00% | 142,000 N/A | 0 -100.00% | 118,000 -44.34% | |
Cash from Investing Activities | 43.4M -54.57% | 95.5M +1,102.43% | 7.9M +107.62% | -104.3M -173.50% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 30.0M -27.85% | 41.6M +3,605.16% | 1.1M -99.42% | 193.7M +163.06% | |
Financials Ratio | |||||
Gross Margin | 94.82% -5.03% | 99.84% +3.34% | 96.62% -0.07% | 96.68% -1.73% | |
Operating Margin | -78.97% -3.97% | -82.24% -7.29% | -88.71% -2.02% | -90.53% +93.30% | |
Return on Assets | -143.71% +280.65% | -37.75% -21.04% | -47.81% -4.04% | -49.83% +24.15% | |
Return on Equity | 81.86% +72.58% | 47.43% -74.66% | 187.23% -45.44% | 343.18% -59.72% | |
Revenue Growth | -20.92% +3,737.37% | -0.55% -92.25% | -7.03% -72.04% | -25.14% -126.71% | |
Current Ratio | 1.12 -33.94% | 1.70 -49.62% | 3.37 -36.63% | 5.31 +42.11% | |
Cash Ratio | 0.66 -2.88% | 0.68 -9.94% | 0.75 -63.35% | 2.05 -20.61% | |
Debt-to-Equity Ratio | -0.40 N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 1.07 N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow